GLAXO2020-04-012020-06-30in-bse-fin:OneOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2020-04-01 2021-03-31 2020-07-01 INR Lakhs First quarter Single segment Pharmaceuticals 2020-04-01 2020-06-30 Unaudited Consolidated 6485900000.00 579200000.00 7065100000.00 1067200000.00 1484200000.00 21900000.00 1519200000.00 10800000.00 217700000.00 1252700000.00 5573700000.00 1491400000.00 0.00 1491400000.00 381100000.00 2000000.00 383100000.00 0.00 1108300000.00 0.00 0.00 0.00 0.00 1108300000.00 -30300000.00 1078000000.00 1078000000.00 0.00 1694100000.00 10 6.54 6.54 0.00 0.00 6.54 6.54 Notes: n n1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th July, 2020. n2. The figures for the preceding 3 months ended 31st March, 2020 are the balancing figures between the audited figures in respect of full financial year and the year to date figures upto the third quarter of the financial year ended 31st March, 2020. n3. The Board of Directors of the Parent in their meeting held on 18th May, 2020 recommended a final dividend of Rs 40/- per equity share (including special dividend of Rs.20/- per share) for the financial year ended 31st March, 2020. The same was approved by the shareholders of the Parent at the Annual General Meeting held on 27th July, 2020. This will result in net cash outflow of Rs.67762 Lakhs. n4. Other income for the quarter ended 30th June, 2020 includes interest on Income tax refund of Rs.4268 Lakhs. Other income for the quarter ended 30th June, 2019 includes interest on Income tax refund of Rs. 863 Lakhs. n5. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the consolidated financial results for the quarter ended 30th June, 2020 n6. The spread of Covid-19 from mid-March is having an unprecedented impact on people and economy. The Group has seen a slowdown in sales across some of its therapeutic areas during the quarter mainly from deferment of vaccination at clinics and slowdown in the non-essential portfolio. The Group has had a steady cash flow through the lockdown period and has been able to meet all its operational needs. There is no impact on capital and financial resources of the Group. None of the assets have been impacted or impaired as a result of the pandemic. With relaxation of the lockdown across various zones of the country, the Group has redeployed its frontline salesforce as per the guidelines received from the Central / State / Municipal authorities. Both at Group and at channel levels, sufficient inventory is maintained to meet patient requirements. n7. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made. n8. Previous periods' figures have been re-grouped / re-classified wherever necessary. Other Expenses 1252700000.00